Deal watch: Roche deal targets glutamate in neurodevelopmental disorders.
Charlotte
C
Harrison
D002648:Child; D002659:Child Development Disorders, Pervasive / Q000188:drug therapy* / Q000503:physiopathology; D003299:Cooperative Behavior; D016503:Drug Delivery Systems; D015195:Drug Design; D004345:Drug Industry / Q000458:organization & administration; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D005600:Fragile X Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D058786:GABA-B Receptor Agonists / Q000494:pharmacology / Q000627:therapeutic use; D018698:Glutamic Acid / Q000378:metabolism*; D006801:Humans; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate / Q000037:antagonists & inhibitors
D018691:Excitatory Amino Acid Antagonists; D058786:GABA-B Receptor Agonists; D064529:Receptor, Metabotropic Glutamate 5; D018094:Receptors, Metabotropic Glutamate; D018698:Glutamic Acid